Immunovant Inc
IMVT23.370USD
+0.020+0.09%
收盤 11/10, 16:00（美東）報價延遲15分鐘
4.00B總市值
虧損本益比TTM
關於 Immunovant Inc 公司
Immunovant, Inc. 是一家臨牀階段免疫學公司。該公司專注於開發自身免疫性疾病患者的治療方法。其產品線包括巴託利單抗和 IMVT-1402，這兩種都是新型的全人源單克隆抗體，靶向新生兒可結晶片段受體 (FcRn)。巴託利單抗是一種皮下注射劑。據觀察，巴託利單抗可降低引起炎症和疾病的免疫球蛋白 G (IgG) 抗體。其候選產品巴託利單抗採用小劑量給藥，並使用 27 號針頭。該公司正在開發用於治療重症肌無力 (MG)、甲狀腺眼病 (TED)、慢性炎症性脫髓鞘性多發性神經病 (CIDP) 和格雷夫斯病 (GD) 的巴託利單抗。其主要候選產品 IMVT-1402 還被觀察到在健康成人中進行的 I 期臨牀試驗中可降低 IgG 抗體水平。 IMVT-1402 是一種抑制 FcRn 的完全人源單克隆抗體。
Immunovant Inc簡介
公司代碼IMVT
公司名稱Immunovant Inc
上市日期May 14, 2019
CEODr. Eric Venker, M.D.
員工數量362
證券類型Ordinary Share
年結日May 14
公司地址320 West 37Th Street
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10018
電話19175803099
網址https://immunovant.com/
公司代碼IMVT
上市日期May 14, 2019
CEODr. Eric Venker, M.D.
Immunovant Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
615.44K
-6.15%
Ms. Melanie Gloria
Ms. Melanie Gloria
Chief Operating Officer
Chief Operating Officer
186.14K
+69.28%
Mr. Douglas J. Hughes
Mr. Douglas J. Hughes
Independent Director
Independent Director
119.58K
-3.96%
Dr. Atul Pande, M.D.
Dr. Atul Pande, M.D.
Independent Director
Independent Director
95.41K
-14.51%
Mr. Andrew J. (Drew) Fromkin
Mr. Andrew J. (Drew) Fromkin
Director
Director
91.91K
-5.09%
Dr. Jay S. Stout, Ph.D.
Dr. Jay S. Stout, Ph.D.
Chief Technology Officer
Chief Technology Officer
77.09K
-5.06%
Dr. Michael Geffner, M.D.
Dr. Michael Geffner, M.D.
Chief Medical Officer
Chief Medical Officer
41.09K
-8.60%
Mr. Jacob (Jake) Bauer
Mr. Jacob (Jake) Bauer
Independent Director
Independent Director
--
--
Mr. Robert G. Susman
Mr. Robert G. Susman
Independent Director
Independent Director
--
--
Mr. Tiago Girao
Mr. Tiago Girao
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
615.44K
-6.15%
Ms. Melanie Gloria
Ms. Melanie Gloria
Chief Operating Officer
Chief Operating Officer
186.14K
+69.28%
Mr. Douglas J. Hughes
Mr. Douglas J. Hughes
Independent Director
Independent Director
119.58K
-3.96%
Dr. Atul Pande, M.D.
Dr. Atul Pande, M.D.
Independent Director
Independent Director
95.41K
-14.51%
Mr. Andrew J. (Drew) Fromkin
Mr. Andrew J. (Drew) Fromkin
Director
Director
91.91K
-5.09%
Dr. Jay S. Stout, Ph.D.
Dr. Jay S. Stout, Ph.D.
Chief Technology Officer
Chief Technology Officer
77.09K
-5.06%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Roivant Sciences Ltd.
55.45%
Fidelity Management & Research Company LLC
10.51%
Deep Track Capital LP
5.45%
T. Rowe Price Investment Management, Inc.
3.95%
The Vanguard Group, Inc.
3.91%
其他
20.74%
持股股東
持股股東
佔比
Roivant Sciences Ltd.
55.45%
Fidelity Management & Research Company LLC
10.51%
Deep Track Capital LP
5.45%
T. Rowe Price Investment Management, Inc.
3.95%
The Vanguard Group, Inc.
3.91%
其他
20.74%
股東類型
持股股東
佔比
Corporation
55.45%
Investment Advisor
26.94%
Hedge Fund
18.10%
Investment Advisor/Hedge Fund
6.09%
Research Firm
2.00%
Individual Investor
1.82%
Private Equity
1.23%
Sovereign Wealth Fund
0.39%
Pension Fund
0.38%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
487
96.71M
55.48%
-16.70M
2025Q2
493
194.27M
113.56%
-2.08M
2025Q1
505
194.81M
114.45%
+16.42M
2024Q4
482
163.29M
104.53%
-8.19M
2024Q3
464
162.18M
111.33%
-1.06M
2024Q2
453
157.67M
108.50%
+1.66M
2024Q1
433
151.47M
104.51%
-605.85K
2023Q4
420
150.13M
103.75%
+991.03K
2023Q3
373
143.75M
105.86%
+4.45M
2023Q2
335
132.11M
101.25%
-11.81M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Roivant Sciences Ltd.
96.65M
55.45%
--
--
Apr 21, 2025
Fidelity Management & Research Company LLC
18.33M
10.51%
+2.20M
+13.67%
Jun 30, 2025
Deep Track Capital LP
9.50M
5.45%
--
--
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
6.88M
3.95%
+984.13K
+16.69%
Jun 30, 2025
The Vanguard Group, Inc.
7.01M
4.02%
+92.23K
+1.33%
Jun 30, 2025
Baker Bros. Advisors LP
5.46M
3.13%
--
--
Jun 30, 2025
Armistice Capital LLC
5.20M
2.98%
+700.00K
+15.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.11M
2.93%
+362.12K
+7.63%
Jun 30, 2025
Point72 Asset Management, L.P.
3.34M
1.91%
+2.53M
+316.03%
Jun 30, 2025
State Street Investment Management (US)
2.83M
1.62%
-257.02K
-8.33%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.73%
SPDR S&P Biotech ETF
0.42%
ProShares Ultra Nasdaq Biotechnology
0.29%
Invesco Nasdaq Biotechnology ETF
0.28%
Direxion Daily S&P Biotech Bull 3X Shares
0.22%
iShares Biotechnology ETF
0.11%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.07%
iShares Russell 2000 Growth ETF
0.07%
Strive Small-Cap ETF
0.05%
BNY Mellon US Small Cap Core Equity ETF
0.05%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.73%
SPDR S&P Biotech ETF
佔比0.42%
ProShares Ultra Nasdaq Biotechnology
佔比0.29%
Invesco Nasdaq Biotechnology ETF
佔比0.28%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.22%
iShares Biotechnology ETF
佔比0.11%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.07%
iShares Russell 2000 Growth ETF
佔比0.07%
Strive Small-Cap ETF
佔比0.05%
BNY Mellon US Small Cap Core Equity ETF
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
